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Vascular endothelial growth factor A (VEGF-A) is classically viewed as 
a key factor in angiogenesis and tissue 
remodeling. However, recent evidence 
suggests a potential role of this growth 
factor in the control of energy metabo-
lism and adipose tissue function. In this 
regard, we and others have described 
the effects of the up and downregula-
tion of VEGF-A in adipose tissue on the 
control of energy homeostasis. VEGF-A 
overexpression protects against diet-
induced obesity and insulin resistance. 
The observation that VEGF-A overex-
pression leads to an increase in brown 
adipose tissue (BAT) thermogenesis and 
also promotes a “BAT-like” phenotype 
in white adipose tissue depots is of par-
ticular relevance for the understanding 
of the mechanisms underlying obesity 
development. In addition, VEGF-A may 
not only have pro-inflammatory but also 
anti-inflammatory properties, with a 
chemotactic activity specific for M2 anti-
inflammatory macrophages. This new 
scientific evidence highlights the impor-
tance that VEGF-A actions on metabo-
lism could have on the design of new 
treatments for obesity, insulin resistance 
and obesity-related disorders.
VEGF is Involved in Energy  
Homeostasis Control
Vascular endothelial growth factor A 
(VEGF-A) is acknowledged as a key mol-
ecule in processes such as vasculogenesis, 
angiogenesis, control of vascular perme-
ability or tissue remodeling.1 However, 
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VEGF-A has also been recognized to 
exert metabolic effects, and both its up 
and downregulation have been described 
to control energy metabolism.2,3 In this 
regard, we have recently reported that 
VEGF-A overexpression in adipose tis-
sue protects transgenic mice against diet-
induced obesity and insulin resistance.2 In 
agreement with our data, Sun et al. dem-
onstrated that a mouse model that allows 
inducible overexpression of VEGF-A in 
adipose tissue is also protected against 
high fat diet-induced insulin resistance.4 
In both models, VEGF-A overproduction 
led to a higher rate of energy expenditure, 
which was probably due to an increase in 
thermogenesis. In our transgenic model,2 
thermogenesis was enhanced mainly in 
brown adipose tissue (BAT), as supported 
by increased protein levels of UCP1 and 
PGC-1α in BAT. However, in the induc-
ible model,4 VEGF-A overexpression 
exerted its effects mostly on white adipose 
tissue (WAT) and, increased thermo-
genesis was the result of a “browning” of 
WAT without changes in BAT depots. All 
these results clearly suggest a potential role 
of VEGF-A in BAT differentiation and 
function. This is of particular importance 
in light of recent evidence demonstrating 
that BAT has physiological relevance in 
adult humans and that obese patients have 
decreased BAT activity.5-7 Thus, increas-
ing thermogenic activity may be of interest 
for the treatment of obesity but requires a 
better understanding of the mechanisms 
underlying the activation of this process in 
BAT. Cold-exposure is one of the inducers 
of non-shivering thermogenesis and this 
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tissue seemed to be specific for M2 mac-
rophages. In line with our findings, a spa-
tiotemporal link between VEGF and M2 
macrophages has been described in several 
processes, in which a parallel increase 
in VEGF and M2 macrophage recruit-
ment has been observed. One example is 
wound healing. Early in wound healing, 
M1 macrophages likely direct the inflam-
matory response that helps clear microbes, 
cellular debris and damaged matrix from 
the wound. When the infection recedes, 
the composition of the local environment 
changes, facilitating either the differentia-
tion of monocytes or the polarization of 
macrophages toward anti-inflammatory 
M2 macrophages. These M2 macro-
phages produce considerable amounts of 
anti-inflammatory cytokines, and also 
VEGF, in order to direct the angiogenic 
response that results in the repair of the 
wound.18,19 Similarly, both VEGF and 
M2 macrophages are involved in tumor 
development. Tumor-associated macro-
phages (TAMs) have been reported to be 
M2 macrophages.20 Indeed, TAMs pro-
duce a host of growth factors that affect 
tumor-cell proliferation, angiogenesis and 
the deposition and dissolution of connec-
tive tissues. These growth factors include 
VEGF and transforming growth factor-β 
(TGF-β).21,22 M2 macrophages and 
VEGF also play a key role in anastomo-
sis, by which endothelial cells from the tip 
of adjacent growing vessels fuse leading 
to the connection of main vessels. This 
process involves tissue-resident macro-
phages located in the vicinity of the vessel 
branches.23 These macrophages are polar-
ized toward the M2 phenotype and release 
pro-angiogenic factors such as VEGF.24
Nevertheless, a causative link between 
expression of VEGF and the presence of 
M2 macrophages has only recently been 
established. We have demonstrated that, 
in adipose tissue, VEGF-A enhances the 
presence of M2 anti-inflammatory mac-
rophages. In order to discern whether 
VEGF-A was acting as a chemoattractant 
for M2 macrophages or if it was promot-
ing the polarization switch from M1 to 
M2 macrophages, bone marrow derived 
macrophages (BMDM) were treated with 
VEGF-A. After treatment with the growth 
factor, we did not find an increase in M2 
markers in comparison with non-treated 
metabolism with a tissue-specific pattern. 
These different actions of VEGF-A may 
rely on different signaling mechanisms, 
which remain to be fully elucidated. In 
addition to VEGFR2, VEGF-A exerts its 
effects through another tyrosine-kinase 
receptor, VEGF receptor 1 (VEGFR1). 
However, VEGF-A has also been recently 
described to regulate adipocyte differ-
entiation independently of VEGFR1 
and VEGFR2.10 Furthermore, not only 
VEGF-A but also VEGF-B may have met-
abolic effects, adding to the complexity 
of the VEGF system.11 VEGF-B controls 
endothelial uptake of fatty acids through 
activation of VEGFR1 and neuropilin-1.11 
Moreover, both genetic and pharmaco-
logical inhibition of VEGF-B signaling in 
mice, have been shown to reduce ectopic 
lipid accumulation, improve peripheral 
insulin sensitivity and muscle glucose 
uptake and preserve islet functional-
ity.12 In addition, compensatory VEGF-B 
upregulation associated to VEGF-A 
downregulation leads to brown-like WAT 
differentiation.3 Altogether, these results 
demonstrate that the VEGF system is 
crucial in the regulation of energy homeo-
stasis but further studies are necessary to 
understand the underlying mechanisms.
VEGF Acts as an  
Anti-Inflammatory M2  
Macrophages Attractant
VEGF is also well-known for being 
involved in inflammatory processes13 but 
little is known about its role in adipose 
tissue inflammation during obesity. It is 
well-accepted that low-grade inflamma-
tion in the adipose tissue can promote 
obesity-associated insulin resistance.14,15 
This process occurs when the recruit-
ment of M1 macrophages promotes the 
change of the anti-inflammatory milieu, 
maintained by M2 macrophages, toward 
an inflammatory enviroment.16 Our work 
points out that VEGF-A has a protective 
effect against adipose tissue inflamma-
tion, by recruiting M2 macrophages to 
adipose depots, thus maintaining an anti-
inflammatory milieu.2
Although VEGF has been widely 
described to be chemotactic for macro-
phages,17 in our animal model, the che-
motactic activity of VEGF-A in adipose 
process involves a hypoxia-independent 
increase in the vascularization of BAT and 
WAT.8 This is accompanied by an increase 
in VEGF-A gene expression that has been 
postulated to be secondary to adrenergic 
stimulation that induces PGC-1α expres-
sion, which in turn can control VEGF-A 
gene promoter.8 However, in our study, 
VEGF-A overexpression per se leads to 
an increase in PGC-1α and UCP-1 levels 
in BAT, suggesting that VEGF-A, either 
directly or indirectly, may trigger thermo-
genesis activation.2 Similarly, inducible 
VEGF-A overexpression leads to upregu-
lation of PGC-1α and UCP-1 in WAT, 
but without effect in BAT.4 Indeed, in the 
inducible VEGF-A overexpressing-model, 
VEGF-A overexpression and increased 
vascularization were exclusive of white 
adipose depots, whereas in our model, 
both effects were present in white and 
brown adipose tissue. This apparent dis-
crepancy between models may be attrib-
uted to the fact that mutant mice obtained 
by classical transgenesis express the trans-
gene during adipose tissue development, 
whereas inducible transgenic mice begin 
to overexpress VEGF-A at 5 weeks of age. 
This also suggests that the timeframe of 
VEGF-A expression is crucial to deter-
minate its action. This idea is consistent 
with the observation that the blockage of 
VEGF-A signaling has opposite effects on 
adipose tissue metabolism depending on 
the pre-existence of obesity in the animal 
model used.4 Indeed, inhibition of VEGF-
A-induced activation of VEGF receptor 2 
(VEGFR2) at the beginning of a high fat 
diet causes an aggravation of metabolic 
alterations in mice. In contrast, the same 
VEGF-A-VEGFR2 blockage in ob/ob 
obese mice leads to reduced body weight 
gain, improved insulin sensitivity and a 
decrease in inflammatory factors.4 These 
results illustrate the complexity of the 
VEGF system, which may have either ben-
eficial or deleterious effects depending on 
the context. For example, VEGF-A over-
expression in β-cell leads to disorganized, 
hypervascularized and fibrotic islets, 
progressive macrophage infiltration and 
proinflammatory cytokine production, 
resulting in impaired insulin secretion, 
decreased β-cell mass and hyperglyce-
mia with age.9 Thus, VEGF-A may have 
opposite actions on inflammation and 
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VEGF-A exerts an anti-inflammatory role 
in adipose tissue, increasing the recruit-
ment of M2 alternatively activated mac-
rophages. Both the reduction of obesity 
and the decrease in pro-inflammatory 
cytokine levels induced by VEGF-A over-
expression would be responsible for the 
amelioration of insulin sensitivity (Fig. 1). 
The elucidation of the precise mechanisms 
by which VEGF-A exerts these actions on 
adipose tissue warrant further studies. A 
better understanding of VEGF-A actions 
on metabolism would be of crucial impor-
tance to the development of treatments 
for obesity, insulin resistance and obesity-
related disorders.
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adipose tissue of obese mice34 and obese 
humans.35 These latter results, and the 
fact that VEGF-A overexpression protects 
mice from diet-induced insulin resistance, 
are in line with a recent report indicat-
ing that morbidly obese subjects with low 
insulin resistance had higher adipose tis-
sue VEGF-A levels than obese subjects 
with high insulin resistance.36 Although 
there are few reports regarding changes 
of VEGF-A expression during diabetes, 
VEGF-A production seems to be decreased 
in cells of Type 2 diabetic patients.37,38 
This clearly suggests a protective role of 
VEGF-A against obesity-induced insulin 
resistance.
Concluding Remarks
Therefore, all these data suggest that 
VEGF-A overexpression in adipose tis-
sue promotes a “BAT-like” phenotype in 
WAT depots and enhances BAT PGC-1α 
and UCP-1 expression, thus increas-
ing thermogenesis and energy expendi-
ture and decreasing obesity. Moreover, 
BMDM.2 These observations therefore 
suggested that VEGF per se was not able 
to induce the switch toward an M2 pheno-
type. In line with our results, it has recently 
been reported that subcutaneous grafts 
of engineered VEGF-A-overexpressing 
keratinocytes have increased amounts of 
macrophages polarized toward an M2 phe-
notype.25 The authors also demonstrate 
that VEGF-A per se is not able to induce 
a polarization switch in BMDM. While 
VEGF-A is needed initially for macro-
phage recruitment, a subsequent activa-
tion by IL-4 and IL-10 is essential for M2 
polarization.25,26 One possible mechanism 
through which VEGF-A could attract M2 
macrophages is through the chemokine 
CXCL12. CXCL12 expression has been 
reported to be linked to VEGF-A expres-
sion27 and recent findings support that 
CXCL12 functions as an anti-inflamma-
tory chemokine.28-30 Moreover, CXCL12 
expression is very high in some pathologic 
conditions associated with hypoxia and in 
proangiogenic environments, such as in 
tumors.28 Indeed, in our transgenic mice, 
the expression of CXCL12 in adipose tis-
sue was upregulated, suggesting that the 
increase in M2 macrophages induced 
by VEGF-A could be mediated through 
CXCL12.2 Thus, altogether these results 
suggest that VEGF-A could, under cer-
tain conditions, act as anti-inflammatory 
molecule.
VEGF May Protect against  
Obesity-Induced Insulin  
Resistance in Humans
The anti-inflammatory properties of 
VEGF-A together with its role in ther-
mogenesis activation may be of particu-
lar relevance during obesity. Although 
VEGF-A expression has been extensively 
measured in obese humans and animal 
models, results are unclear, and there are 
conflicting reports regarding the local 
and systemic levels of VEGF during obe-
sity. Several reports argue that VEGF-A 
concentration in serum correlates signifi-
cantly with BMI,31,32 with higher VEGF-A 
levels observed in overweight and obese 
subjects and animal models. However, 
other authors have failed to reproduce 
these results33 and a few studies have 
reported decreased VEGF-A expression in 
Figure 1. Schematic representation of the impact of VeGF-A overexpression in adipose tissue on 
insulin resistance. VeGF-A overexpression promotes a “BAt-like” phenotype in WAt depots and 
enhances PGC-1α and UCP-1 expression in BAt, leading to increased thermogenesis and energy 
expenditure and reduced obesity. VeGF-A overexpression also exerts its action on macrophages 
by increasing the recruitment of M2 anti-inflammatory macrophages to fat depots. the decreased 
obesity and the anti-inflammatory milieu induced by VeGF-A in adipose tissue may be responsible 
for the reduction of insulin resistance in transgenic mice.
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